首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >In the Era of BCR-ABL1 Inhibitors, Are We Closing the Survival Gap Between Allogeneic Hematopoietic Cell Transplantation and Chemotherapy for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in First Complete Remission?

【24h】

In the Era of BCR-ABL1 Inhibitors, Are We Closing the Survival Gap Between Allogeneic Hematopoietic Cell Transplantation and Chemotherapy for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in First Complete Remission?

机译：在BCR-ABL1抑制剂的时代，我们是否在首次完全缓解中依赖于一体化造血细胞移植和化疗的异种造血细胞移植和化疗之间的存活差距？

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation》 |2018年第4期|共2页
作者
Wieduwilt Matthew J.;
展开▼
作者单位

Univ Calif San Diego Moores Canc Ctr 3855 Hlth Sci Dr 0960 La Jolla CA 92093 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. In the Era of BCR-ABL1 Inhibitors, Are We Closing the Survival Gap Between Allogeneic Hematopoietic Cell Transplantation and Chemotherapy for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in First Complete Remission? [J] . Wieduwilt Matthew J. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2018,第4期

机译：在BCR-ABL1抑制剂的时代，我们是否在首次完全缓解中依赖于一体化造血细胞移植和化疗的异种造血细胞移植和化疗之间的存活差距？
2. Retrospective analysis of Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic hematopoietic stem cell transplant versus chemotherapy combined with tyrosine kinase inhibitor [J] . Togasaki Emi, Shono Katsuhiro, Onoda Masahiro, Leukemia and lymphoma . 2015,第1期

机译：异基因造血干细胞移植联合化疗联合酪氨酸激酶抑制剂治疗费城染色体阳性急性淋巴细胞白血病的回顾性分析
3. Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era [J] . Xue Yu-juan, Cheng Yi-fei, Lu Ai-dong, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2019,第8期

机译：同种异体造血干细胞移植，尤其是寄和杂志，可改善酪氨酸激酶抑制剂时代的费城染色体阳性急性淋巴细胞白血病的高危小儿患者的长期存活
4. HIGH-DOSE MELPHALAN CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN 65 PATIENTS WITH AL AMYLOIDOSIS: ORGAN PROGRESSION CAN BE DELAYED IN PATIENTS REACHING COMPLETE REMISSION [C] . SO Schonland, J.B Dengler, M Hundemer, International Symposium on Amyloidosis . 2008

机译：在65例Al淀粉样蛋白患者中，具有自体蛋白化疗的高剂量蛋白化疗：器官进展可以延迟达到完全缓解的患者
5. Retrospective analysis of survival and treatment related mortality following a myeloablative hematopoietic stem cell transplant in childhood acute lymphoblastic leukemia. [D] . Dasgupta, Sreejeta. 2010

机译：儿童急性淋巴细胞白血病清髓性造血干细胞移植后生存和治疗相关死亡率的回顾性分析。
6. Comparison of microtransplantation chemotherapy and allogeneic transplantation in post-remission therapy for Philadelphia chromosome-positive acute lymphoblastic leukemia [O] . Bo Cai, Qiyun Sun, Jianhui Qiao, 2020

机译：小植物染色体阳性急性淋巴细胞白血病乳化后治疗中微碾压化疗和同种异体移植的比较
7. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for blood and marrow transplantation [O] . Giebel Sebastian, Czyz Anna, Ottmann Oliver, 2016

机译：费城染色体阳性急性淋巴细胞白血病患者使用酪氨酸激酶抑制剂预防异基因造血干细胞移植后复发：欧洲血液和骨髓移植学会急性白血病工作组的立场声明

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号